Ken Griffin Adaptimmune Therapeutics PLC Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.92 - $1.39 $35,604 - $53,792	-38,700 Reduced 57.93%	28,100 $26,000
Q2 2024 Aug 14, 2024	BUY	$0.83 - $1.47 $19,920 - $35,280	24,000 Added 56.07%	66,800 $65,000
Q1 2024 May 15, 2024	BUY	$0.7 - $1.75 $29,959 - $74,900	42,800 New	42,800 $67,000
Q3 2023 Nov 14, 2023	SELL	$0.73 - $1.04 $4,215 - $6,006	-5,775 Reduced 93.52%	400 $0
Q2 2023 Aug 14, 2023	SELL	$0.9 - $1.51 $3,442 - $5,775	-3,825 Reduced 38.25%	6,175 $5,000
Q1 2023 May 15, 2023	SELL	$1.06 - $2.16 $1,166 - $2,376	-1,100 Reduced 9.91%	10,000 $10,000
Q4 2022 Feb 14, 2023	SELL	$1.05 - $2.53 $11,550 - $27,829	-11,000 Reduced 49.77%	11,100 $16,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $2.41 $38,690 - $87,965	-36,500 Reduced 62.29%	22,100 $24,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $108M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.